Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide
0.1.0 - CI Build
Gravitate Health FHIR Implementation Guide, published by Gravitate Health Project. This guide is not an authorized publication; it is the continuous build for version 0.1.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/joofio/test-epi-composition/ and changes regularly. See the Directory of published versions
{
"resourceType" : "Bundle",
"id" : "bundlepackageleaflet-en-8774c315768c11f1f8299f9a299778e8",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Bundle-uv-epi"
]
},
"language" : "en",
"identifier" : {
"system" : "http://ema.europa.eu/identifier",
"value" : "None"
},
"type" : "document",
"timestamp" : "2023-06-27T10:09:22Z",
"entry" : [
{
"fullUrl" : "Composition/composition-en-8774c315768c11f1f8299f9a299778e8",
"resource" : {
"resourceType" : "Composition",
"id" : "composition-en-8774c315768c11f1f8299f9a299778e8",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/Composition-uv-epi"
]
},
"language" : "en",
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\" xml:lang=\"en\" lang=\"en\"><a name=\"Composition_composition-en-8774c315768c11f1f8299f9a299778e8\"> </a><p class=\"res-header-id\"><b>Generated Narrative: Composition composition-en-8774c315768c11f1f8299f9a299778e8</b></p><a name=\"composition-en-8774c315768c11f1f8299f9a299778e8\"> </a><a name=\"hccomposition-en-8774c315768c11f1f8299f9a299778e8\"> </a><a name=\"composition-en-8774c315768c11f1f8299f9a299778e8-en-US\"> </a><div style=\"display: inline-block; background-color: #d9e0e7; padding: 6px; margin: 4px; border: 1px solid #8da1b4; border-radius: 5px; line-height: 60%\"><p style=\"margin-bottom: 0px\">Language: en</p><p style=\"margin-bottom: 0px\">Profile: <a href=\"https://build.fhir.org/ig/HL7/emedicinal-product-info/StructureDefinition-Composition-uv-epi.html\">Composition (ePI)</a></p></div><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/944/003</p><p><b>status</b>: Final</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi/ 100000155538}\">Package Leaflet</span></p><p><b>category</b>: <span title=\"Codes:{http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs R}\">Raw</span></p><p><b>date</b>: 2022-02-16 13:28:17+0000</p><p><b>author</b>: <a href=\"Organization-mah-ema.html\">Organization ACME industry</a></p><p><b>title</b>: TEST PURPOSES ONLY - abasaglar</p><h3>Attesters</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Mode</b></td><td><b>Time</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{http://hl7.org/fhir/composition-attestation-mode official}\">Official</span></td><td>2022-02-16 13:28:17+0000</td></tr></table></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/14/944/003"
}
],
"status" : "final",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package Leaflet"
},
"category" : [
{
"coding" : [
{
"system" : "http://hl7.eu/fhir/ig/gravitate-health/CodeSystem/epicategory-cs",
"code" : "R",
"display" : "Raw"
}
]
}
],
"subject" : [
{
"reference" : "MedicinalProductDefinition/mp8774c315768c11f1f8299f9a299778e8"
}
],
"date" : "2022-02-16T13:28:17Z",
"author" : [
{
🔗 "reference" : "Organization/mah-ema"
}
],
"title" : "TEST PURPOSES ONLY - abasaglar",
"attester" : [
{
"mode" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/composition-attestation-mode",
"code" : "official"
}
]
},
"time" : "2022-02-16T13:28:17Z"
}
],
"section" : [
{
"title" : "B. Package Leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "B. Package Leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\">unavailable</div>"
},
"emptyReason" : {
"coding" : [
{
"system" : "http://terminology.hl7.org/CodeSystem/list-empty-reason",
"code" : "unavailable"
}
]
},
"section" : [
{
"title" : "Package leaflet: Information for the user",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "Package leaflet: Information for the user"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"></div>"
}
},
{
"title" : "What is in this leaflet",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "What is in this leaflet"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>What is in this leaflet</p><ol type=\"1\"><li>What ABASAGLAR is and what it is used for</li><li>What you need to know before you use ABASAGLAR</li><li>How to use ABASAGLAR</li><li>Possible side effects</li><li>How to store ABASAGLAR</li><li>Contents of the pack and other information</li></ol></div>"
}
},
{
"title" : "1. What abasaglar is and what it is used for",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "1. What abasaglar is and what it is used for"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>ABASAGLAR contains insulin glargine. This is a modified insulin, very similar to human insulin.</p><p>ABASAGLAR is used to treat diabetes mellitus in adults, adolescents and children aged 2 years and above.</p><p>Diabetes mellitus is a disease where your body does not produce enough insulin to control the level of blood sugar. Insulin glargine has a long and steady blood-sugar-lowering action.</p></div>"
}
},
{
"title" : "2. What you need to know before you take abasaglar",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "2. What you need to know before you take abasaglar"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Do not use ABASAGLAR If you are allergic to insulin glargine or any of the other ingredients of this medicine (listed in section 6).</p><p>Warnings and precautions<br/>Talk to your doctor, pharmacist or nurse before using ABASAGLAR. Follow closely the instructions for posology, monitoring (blood and urine tests), diet and physical activity (physical work and exercise) as discussed with your doctor.</p><p>If your blood sugar is too low (hypoglycaemia), follow the guidance for hypoglycaemia (see box at the end of this leaflet).</p><p>Skin changes at the injection site. The injection site should be rotated to prevent skin changes such as lumps under the skin. The insulin may not work well if you inject into a lumpy area (See How to use Abasaglar). Contact your doctor if you are currently injecting into a lumpy area before you start injecting into a different area. Your doctor may tell you to check your blood sugar more closely, and to adjust your insulin or your other antidiabetic medications dose. Travel Before travelling consult your doctor. You may need to talk about:</p><ul><li></li></ul><h2 id=\"the-availability-of-your-insulin-in-the-country-you-are-visiting\">the availability of your insulin in the country you are visiting,</h2><h2 id=\"supplies-of-insulin-etc\">supplies of insulin etc.</h2><h2 id=\"correct-storage-of-your-insulin-while-travelling\">correct storage of your insulin while travelling,</h2><h2 id=\"timing-of-meals-and-insulin-administration-while-travelling\">timing of meals and insulin administration while travelling,</h2><h2 id=\"the-possible-effects-of-changing-to-different-time-zones\">the possible effects of changing to different time zones,</h2><h2 id=\"possible-new-health-risks-in-the-countries-to-be-visited\">possible new health risks in the countries to be visited,</h2><p>what you should do in emergency situations when you feel unwell or become ill.</p><p>Illnesses and injuries In the following situations, the management of your diabetes may require a lot of care (for example, adjustment to insulin dose, blood and urine tests):</p><ul><li></li></ul><h2 id=\"if-you-are-ill-or-have-a-major-injury-then-your-blood-sugar-level-may-increase-hyperglycaemia\">If you are ill or have a major injury then your blood sugar level may increase (hyperglycaemia).</h2><p>If you are not eating enough your blood sugar level may become too low (hypoglycaemia). In most cases you will need a doctor. Make sure that you contact a doctor early.</p><p>If you have type 1 diabetes (insulin dependent diabetes mellitus), do not stop your insulin and continue to get enough carbohydrates. Always tell people who are caring for you or treating you that you require insulin.</p><p>Insulin treatment can cause the body to produce antibodies to insulin (substances that act against insulin). However, only very rarely, this will require a change to your insulin dose.</p><p>Some patients with long-standing type 2 diabetes mellitus and heart disease or previous stroke who were treated with pioglitazone and insulin experienced the development of heart failure. Inform your doctor as soon as possible if you experience signs of heart failure such as unusual shortness of breath or rapid increase in weight or localised swelling (oedema).</p><p>Insulin mix-ups You must always check the pack and the insulin label before each injection to avoid mix-ups between ABASAGLAR and other insulins.</p><p>Children There is no experience with the use of ABASAGLAR in children below the age of 2 years.</p><p>Other medicines and ABASAGLAR Some medicines cause changes in the blood sugar level (decrease, increase or both depending on the situation). In each case, it may be necessary to adjust your insulin dose to avoid blood sugar levels that are either too low or too high. Be careful when you start or stop taking another medicine. Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. Before taking a medicine ask your doctor if it can affect your blood sugar level and what action, if any, you need to take.</p><p>Medicines that may cause your blood sugar level to fall (hypoglycaemia) include:</p><ul><li></li></ul><h2 id=\"all-other-medicines-to-treat-diabetes\">all other medicines to treat diabetes,</h2><h2 id=\"angiotensin-converting-enzyme-ace-inhibitors-used-to-treat-certain-heart-conditions-or-high-blood-pressure\">angiotensin converting enzyme (ACE) inhibitors (used to treat certain heart conditions or high blood pressure),</h2><h2 id=\"disopyramide-used-to-treat-certain-heart-conditions\">disopyramide (used to treat certain heart conditions),</h2><h2 id=\"fluoxetine-used-to-treat-depression\">fluoxetine (used to treat depression),</h2><h2 id=\"fibrates-used-to-lower-high-levels-of-blood-lipids\">fibrates (used to lower high levels of blood lipids),</h2><h2 id=\"monoamine-oxidase-mao-inhibitors-used-to-treat-depression\">monoamine oxidase (MAO) inhibitors (used to treat depression),</h2><h2 id=\"pentoxifylline-propoxyphene-salicylates-such-as-aspirin-used-to-relieve-pain-and-lower-fever\">pentoxifylline, propoxyphene, salicylates (such as aspirin, used to relieve pain and lower fever),</h2><h2 id=\"somatostatin-analogues-such-as-octreotide-used-to-treat-an-uncommon-condition-in-which-you-make-too-much-growth-hormone\">somatostatin analogues (such as octreotide, used to treat an uncommon condition in which you make too much growth hormone),</h2><p>sulphonamide antibiotics.</p><p>Medicines that may cause your blood sugar level to rise (hyperglycaemia) include:</p><ul><li></li></ul><h2 id=\"corticosteroids-such-as-cortisone-used-to-treat-inflammation\">corticosteroids (such as \"cortisone\" used to treat inflammation),</h2><h2 id=\"danazol-medicine-acting-on-ovulation\">danazol (medicine acting on ovulation),</h2><h2 id=\"diazoxide-used-to-treat-high-blood-pressure\">diazoxide (used to treat high blood pressure),</h2><h2 id=\"diuretics-used-to-treat-high-blood-pressure-or-excessive-fluid-retention\">diuretics (used to treat high blood pressure or excessive fluid retention),</h2><h2 id=\"glucagon-pancreas-hormone-used-to-treat-severe-hypoglycaemia\">glucagon (pancreas hormone used to treat severe hypoglycaemia),</h2><h2 id=\"isoniazid-used-to-treat-tuberculosis\">isoniazid (used to treat tuberculosis),</h2><h2 id=\"oestrogens-and-progestogens-such-as-in-the-contraceptive-pill-used-for-birth-control\">oestrogens and progestogens (such as in the contraceptive pill used for birth control),</h2><h2 id=\"phenothiazine-derivatives-used-to-treat-psychiatric-disorders\">phenothiazine derivatives (used to treat psychiatric disorders),</h2><h2 id=\"somatropin-growth-hormone\">somatropin (growth hormone),</h2><h2 id=\"sympathomimetic-medicines-such-as-epinephrine-adrenaline-salbutamol-terbutaline-used-to-treat-asthma\">sympathomimetic medicines (such as epinephrine [adrenaline], salbutamol, terbutaline used to treat asthma),</h2><h2 id=\"thyroid-hormones-used-to-treat-thyroid-gland-disorders\">thyroid hormones (used to treat thyroid gland disorders),</h2><h2 id=\"atypical-antipsychotic-medicines-such-as-clozapine-olanzapine\">atypical antipsychotic medicines (such as clozapine, olanzapine),</h2><p>protease inhibitors (used to treat HIV).</p><p>Your blood sugar level may either rise or fall if you take:</p><ul><li></li></ul><h2 id=\"beta-blockers-used-to-treat-high-blood-pressure\">beta-blockers (used to treat high blood pressure),</h2><h2 id=\"clonidine-used-to-treat-high-blood-pressure\">clonidine (used to treat high blood pressure),</h2><p>lithium salts (used to treat psychiatric disorders).</p><p>Pentamidine (used to treat some infections caused by parasites) may cause hypoglycaemia which may sometimes be followed by hyperglycaemia.</p><p>Beta-blockers like other sympatholytic medicines (such as clonidine, guanethidine, and reserpine) may weaken or suppress entirely the first warning symptoms which help you to recognise a hypoglycaemia.<br/>If you are not sure whether you are taking one of those medicines ask your doctor or pharmacist.</p><p>ABASAGLAR with alcohol Your blood sugar levels may either rise or fall if you drink alcohol.</p><p>Pregnancy and breast-feeding Ask your doctor or pharmacist for advice before taking any medicine. Inform your doctor if you are planning to become pregnant, or if you are already pregnant. Your insulin dose may need to be changed during pregnancy and after giving birth. Particularly careful control of your diabetes, and prevention of hypoglycaemia, is important for the health of your baby. If you are breast-feeding consult your doctor as you may require adjustments in your insulin doses and your diet.</p><p>Driving and using machines Your ability to concentrate or react may be reduced if:</p><ul><li></li></ul><h2 id=\"you-have-hypoglycaemia-low-blood-sugar-levels\">you have hypoglycaemia (low blood sugar levels),</h2><h2 id=\"you-have-hyperglycaemia-high-blood-sugar-levels\">you have hyperglycaemia (high blood sugar levels),</h2><p>you have problems with your sight. Keep this possible problem in mind in all situations where you might put yourself and others at risk (such as driving a car or using machines). You should contact your doctor for advice on driving if:</p><ul><li></li></ul><h2 id=\"you-have-frequent-episodes-of-hypoglycaemia\">you have frequent episodes of hypoglycaemia,</h2><p>the first warning symptoms which help you to recognise hypoglycaemia are reduced or absent.</p><p>ABASAGLAR contains sodium This medicine contains less than 1 mmol (23 mg) sodium per dose, which means it is essentially sodium-free .</p></div>"
}
},
{
"title" : "3. How to take abasaglar",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "3. How to take abasaglar"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Always use this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure. Although ABASAGLAR contains the same active substance as Toujeo (insulin glargine 300 units/mL), these medicines are not interchangeable. The switch from one insulin therapy to another requires medical prescription, medical supervision and blood glucose monitoring. Please consult your doctor for further information.</p><p>Dose Based on your life-style and the results of your blood sugar (glucose) tests and your previous insulin usage, your doctor will:</p><ul><li></li></ul><h2 id=\"determine-how-much-abasaglar-per-day-you-will-need-and-at-what-time\">determine how much ABASAGLAR per day you will need and at what time,</h2><h2 id=\"tell-you-when-to-check-your-blood-sugar-level-and-whether-you-need-to-carry-out-urine-tests\">tell you when to check your blood sugar level, and whether you need to carry out urine tests,</h2><p>tell you when you may need to inject a higher or lower dose of ABASAGLAR.</p><p>ABASAGLAR is a long-acting insulin. Your doctor may tell you to use it in combination with a short- acting insulin or with tablets used to treat high blood sugar levels.</p><p>Many factors may influence your blood sugar level. You should know these factors so that you are able to react correctly to changes in your blood sugar level and to prevent it from becoming too high or too low. See the box at the end of this leaflet for further information.</p><p>Use in children and adolescents ABASAGLAR can be used in adolescents and children aged 2 years and above. Use this medicine exactly as your doctor has told you.</p><p>Frequency of administration You need one injection of ABASAGLAR every day, at the same time of the day.</p><p>Method of administration ABASAGLAR is injected under the skin. Do NOT inject ABASAGLAR in a vein, since this will change its action and may cause hypoglycaemia.</p><p>Your doctor will show you in which area of the skin you should inject ABASAGLAR. With each injection, change the puncture site within the particular area of skin that you are using.</p><p>How to handle the cartridges The ABASAGLAR cartridges are to be used only in Lilly insulin pens to ensure you get the correct dose. Not all of these pens may be marketed in your country.</p><p>The pen should be used as recommended in the information provided.</p><p>The instructions for using the pen must be followed carefully for loading the cartridge, attaching the needle, and administering the insulin injection.</p><p>To prevent the possible transmission of disease, each pen must be used by one patient only.</p><p>Look at the cartridge before you use it. Only use it if the solution is clear, colourless and water-like, and has no visible particles in it. Do not shake or mix it before use.</p><p>Always use a new cartridge if you notice that your blood sugar control is unexpectedly getting worse. This is because the insulin may have lost some of its effectiveness. If you think you may have a problem with ABASAGLAR, have it checked by your doctor or pharmacist.</p><p>Special care before injection Before injection remove any air bubbles (see instructions for using the pen).</p><p>Make sure that neither alcohol nor other disinfectants or other substances contaminate the insulin.</p><p>Do not re-fill and re-use empty cartridges. Do not add any other insulin to the cartridge. Do not mix ABASAGLAR with any other insulins or medicines. Do not dilute it. Mixing or diluting may change the action of ABASAGLAR.</p><p>Problems with the insulin pen?</p><p>Refer to the instructions for using the pen.</p><p>If the insulin pen is damaged or not working properly (due to mechanical defects) it has to be discarded, and a new insulin pen has to be used.</p><h2 id=\"if-you-use-more-abasaglar-than-you-should\">If you use more ABASAGLAR than you should</h2><p>If you have injected too much ABASAGLAR or are unsure how much you have injected, your blood sugar level may become too low (hypoglycaemia). Check your blood sugar frequently. In general, to prevent hypoglycaemia you must eat more food and monitor your blood sugar. For information on the treatment of hypoglycaemia, see box at the end of this leaflet.</p><h2 id=\"if-you-forget-to-use-abasaglar\">If you forget to use ABASAGLAR</h2><h2 id=\"if-you-have-missed-a-dose-of-abasaglar-or-if-you-have-not-injected-enough-insulin-or-are-unsure-how-much-you-have-injected-your-blood-sugar-level-may-become-too-high-hyperglycaemia-check-your-blood-sugar-frequently-for-information-on-the-treatment-of-hyperglycaemia-see-box-at-the-end-of-this-leaflet\">If you have missed a dose of ABASAGLAR or if you have not injected enough insulin or are unsure how much you have injected, your blood sugar level may become too high (hyperglycaemia). Check your blood sugar frequently. For information on the treatment of hyperglycaemia, see box at the end of this leaflet.</h2><p>Do not take a double dose to make up for a forgotten dose.</p><p>After injecting If you are unsure how much you have injected then check your blood sugar levels before deciding if you need another injection.</p><p>If you stop using ABASAGLAR This could lead to severe hyperglycaemia (very high blood sugar) and ketoacidosis (build-up of acid in the blood because the body is breaking down fat instead of sugar). Do not stop ABASAGLAR without speaking to a doctor, who will tell you what needs to be done.</p><p>If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p></div>"
}
},
{
"title" : "4. Possible side effects",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "4. Possible side effects"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you notice signs of your blood sugar being too low (hypoglycaemia), take the action to increase your blood sugar levels immediately. Hypoglycaemia (low blood sugar) can be very serious and is very common with insulin treatment (may affect more than 1 in 10 people). Low blood sugar means that there is not enough sugar in your blood. If your blood sugar level falls too low, you may pass out (become unconscious). Serious hypoglycaemia may cause brain damage and may be life-threatening. For more information, see the box at the end of this leaflet.</p><p>Severe allergic reactions (rare, may affect up to 1 in 1,000 people) the signs may include large-scale skin reactions (rash and itching all over the body), severe swelling of skin or mucous membranes (angiooedema), shortness of breath, a fall in blood pressure with rapid heartbeat and sweating. Severe allergic reactions to insulins may become life-threatening. Tell a doctor straight away if you notice signs of severe allergic reaction.</p><p>Skin changes at the injection site If you inject insulin too often at the same place, the fatty tissue may shrink (lipoatrophy, may affect up to 1 in 100 people) or thicken (lipohypertrophy, may affect up to 1 in 10 people). Lumps under the skin may also be caused by build-up of a protein called amyloid (cutaneous amyloidosis, how often they occur is not known). The insulin may not work very well if you inject into a lumpy area. Change the injection site with each injection to help prevent these skin changes. Common side effects (may affect up to 1 in 10 people)</p><ul><li>Skin and allergic reactions at the injection site</li></ul><p>The signs may include reddening, unusually intense pain when injecting, itching, hives, swelling or inflammation. They can spread around the injection site. Most minor reactions to insulins usually disappear in a few days to a few weeks.</p><p>Rare side effects (may affect up to 1 in 1,000 people)</p><ul><li>Eye reactions</li></ul><p>A marked change (improvement or worsening) in your blood sugar control can disturb your vision temporarily. If you have proliferative retinopathy (an eye disease related to diabetes) severe hypoglycaemic attacks may cause temporary loss of vision.</p><ul><li>General disorders</li></ul><p>In rare cases, insulin treatment may also cause temporary build-up of water in the body, with swelling in the calves and ankles.</p><p>Very rare side-effects (may affect up to1 in 10,000 people) In very rare cases, dysgeusia (taste disorders) and myalgia (muscular pain) can occur.</p><p>Use in children and adolescents In general, the side effects in children and adolescents of 18 years of age or less are similar to those seen in adults.</p><p>Complaints of injection site reactions (injection site pain, injection site reaction) and skin reactions (rash, urticaria) are reported relatively more frequently in children and adolescents of 18 years of age or less than in adults.</p><p>Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via the national reporting system listed in Appendix V. By reporting side effects you can help provide more information on the safety of this medicine.</p></div>"
}
},
{
"title" : "5. How to store abasaglar",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "5. How to store abasaglar"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the label of the cartridge after EXP . The expiry date refers to the last day of that month.</p><p>Unopened cartridges Store in a refrigerator (2 C - 8 C). Do not freeze.<br/>Do not put ABASAGLAR next to the freezer compartment or a freezer pack.<br/>Keep the cartridge in the outer carton in order to protect from light.</p><p>In-use cartridges Cartridges in use (in the insulin pen) or carried as a spare may be stored for a maximum of 28 days up to 30 C and away from direct heat or direct light. The cartridge in use must not be stored in a refrigerator. Do not use it after this time period.</p><p>Do not use ABASAGLAR if you notice particles in it. Only use ABASAGLAR if the solution is clear, colourless and water like.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p></div>"
}
},
{
"title" : "6. Contents of the pack and other information",
"code" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi/",
"code" : "100000155538"
}
],
"text" : "6. Contents of the pack and other information"
},
"text" : {
"status" : "additional",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2 id=\"what-abasaglar-contains\">What ABASAGLAR contains</h2><h2 id=\"the-active-substance-is-insulin-glargine-each-millilitre-of-the-solution-contains-100-units-of-the-active-substance-insulin-glargine-equivalent-to-364-mg\">The active substance is insulin glargine. Each millilitre of the solution contains 100 units of the active substance insulin glargine (equivalent to 3.64 mg).</h2><p>The other ingredients are: zinc oxide, metacresol, glycerol, sodium hydroxide (see section 2 ABASAGLAR contains sodium ), hydrochloric acid and water for injections.</p><p>What ABASAGLAR looks like and contents of the pack ABASAGLAR 100 units/mL solution for injection in a cartridge is a clear and colourless solution.</p><p>ABASAGLAR comes in a special cartridge to be used only in a Lilly insulin pen. Each cartridge contains 3 mL of solution for injection (equivalent to 300 units) and they are available in packs of 5 and 10 cartridges.</p><p>Not all pack sizes may be marketed.</p><p>Marketing Authorisation Holder<br/>Eli Lilly Nederland B.V., Papendorpseweg 83, 3528 BJ Utrecht, The Netherlands.</p><p>Manufacturer Lilly France S.A.S., rue du Colonel Lilly, F-67640 Fegersheim, France. Eli Lilly Italia S.p.A., Via Gramsci 731-733, 50019 Sesto Fiorentino, (FI) Italy.</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p><p>Belgi /Belgique/Belgien Eli Lilly Benelux S.A./N.V. T l/Tel: + 32-(0)2 548 84 Lietuva Eli Lilly Lietuva Tel. +370 (5) 2649<br/>\" \" . . -<br/>. +359 2 491 41 Luxembourg/Luxemburg Eli Lilly Benelux S.A./N.V. T l/Tel: + 32-(0)2 548 84 esk republika ELI LILLY R, s.r.o. Tel: + 420 234 664 Magyarorsz g Lilly Hung ria Kft. Tel: + 36 1 328 5Danmark Eli Lilly Danmark A/S<br/>Tlf: +45 45 26 60 Malta Charles de Giorgio Ltd. Tel: + 356 25600 Deutschland Lilly Deutschland GmbH Tel. + 49-(0) 6172 273 2Nederland Eli Lilly Nederland B.V.<br/>Tel: + 31-(0) 30 60 25 Eesti Eli Lilly Nederland B.V. Tel: +372 6 817 Norge Eli Lilly Norge A.S.<br/>Tlf: + 47 22 88 18</p><ul><li>. . . .<br/>: +30 210 629 4 sterreich Eli Lilly Ges.m.b.H.<br/>Tel: + 43-(0) 1 711 Espa a Lilly S.A. Tel: + 34-91 663 50 Polska Eli Lilly Polska Sp. z o.o. Tel: +48 22 440 33 France Lilly France<br/>T l: +33-(0) 1 55 49 34 Portugal Lilly Portugal Produtos Farmac uticos, Lda Tel: + 351-21-4126Hrvatska Eli Lilly Hrvatska d.o.o. Tel: +385 1 2350 Rom nia Eli Lilly Rom nia S.R.L. Tel: + 40 21 4023Ireland Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4Slovenija Eli Lilly farmacevtska dru ba, d.o.o. Tel: +386 (0)1 580 00 sland Icepharma hf. S mi + 354 540 8Slovensk republika Eli Lilly Slovakia s.r.o. Tel: + 421 220 663 Italia Eli Lilly Italia S.p.A. Tel: + 39- 055 42Suomi/Finland Oy Eli Lilly Finland Ab<br/>Puh/Tel: + 358-(0) 9 85 45<br/>Phadisco Ltd<br/>: +357 22 715Sverige Eli Lilly Sweden AB Tel: + 46-(0) 8 7378Latvija Eli Lilly (Suisse) S.A P rst vniec ba Latvij Tel: +371 67364United Kingdom (Northern Ireland) Eli Lilly and Company (Ireland) Limited Tel: + 353-(0) 1 661 4This leaflet was last revised in</li></ul><p>Other sources of information</p><p>Detailed information on this medicine is available on the European Medicines Agency web site:</p></div>"
}
}
]
}
]
}
},
{
"fullUrl" : "MedicinalProductDefinition/mp8774c315768c11f1f8299f9a299778e8",
"resource" : {
"resourceType" : "MedicinalProductDefinition",
"id" : "mp8774c315768c11f1f8299f9a299778e8",
"meta" : {
"profile" : [
🔗 "http://hl7.org/fhir/uv/emedicinal-product-info/StructureDefinition/MedicinalProductDefinition-uv-epi"
]
},
"text" : {
"status" : "generated",
"div" : "<div xmlns=\"http://www.w3.org/1999/xhtml\"><a name=\"MedicinalProductDefinition_mp8774c315768c11f1f8299f9a299778e8\"> </a><p class=\"res-header-id\"><b>Generated Narrative: MedicinalProductDefinition mp8774c315768c11f1f8299f9a299778e8</b></p><a name=\"mp8774c315768c11f1f8299f9a299778e8\"> </a><a name=\"hcmp8774c315768c11f1f8299f9a299778e8\"> </a><a name=\"mp8774c315768c11f1f8299f9a299778e8-en-US\"> </a><p><b>identifier</b>: <code>http://ema.europa.eu/identifier</code>/EU/1/14/944/003</p><p><b>type</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-type MedicinalProduct}\">Medicinal Product</span></p><p><b>domain</b>: <span title=\"Codes:{http://hl7.org/fhir/medicinal-product-domain Human}\">Human use</span></p><p><b>status</b>: <span title=\"Codes:{http://hl7.org/fhir/publication-status active}\">active</span></p><p><b>legalStatusOfSupply</b>: <span title=\"Codes:{https://spor.ema.europa.eu/rmswi 100000072084}\">Medicinal product subject to medical prescription</span></p><blockquote><p><b>name</b></p><p><b>productName</b>: ABASAGLAR 100 units/mL solution for injection in a cartridge</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000001}\">Full name</span></p><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000002}\">Invented name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000003}\">Scientific name part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000004}\">Strength part</span></p></blockquote><blockquote><p><b>part</b></p><p><b>part</b>: nan</p><p><b>type</b>: <span title=\"Codes:{https://spor.ema.europa.eu/lists/220000000000 220000000005}\">Pharmaceutical dose form part</span></p></blockquote><h3>Usages</h3><table class=\"grid\"><tr><td style=\"display: none\">-</td><td><b>Country</b></td><td><b>Jurisdiction</b></td><td><b>Language</b></td></tr><tr><td style=\"display: none\">*</td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:iso:std:iso:3166 EU}\">EU</span></td><td><span title=\"Codes:{urn:ietf:bcp:47 en}\">en</span></td></tr></table></blockquote></div>"
},
"identifier" : [
{
"system" : "http://ema.europa.eu/identifier",
"value" : "EU/1/14/944/003"
}
],
"type" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-type",
"code" : "MedicinalProduct",
"display" : "Medicinal Product"
}
]
},
"domain" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/medicinal-product-domain",
"code" : "Human",
"display" : "Human use"
}
]
},
"status" : {
"coding" : [
{
"system" : "http://hl7.org/fhir/publication-status",
"code" : "active",
"display" : "active"
}
]
},
"legalStatusOfSupply" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/rmswi",
"code" : "100000072084",
"display" : "Medicinal product subject to medical prescription"
}
]
},
"name" : [
{
"productName" : "ABASAGLAR 100 units/mL solution for injection in a cartridge",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000001",
"display" : "Full name"
}
]
},
"part" : [
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000002",
"display" : "Invented name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000003",
"display" : "Scientific name part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000004",
"display" : "Strength part"
}
]
}
},
{
"part" : "nan",
"type" : {
"coding" : [
{
"system" : "https://spor.ema.europa.eu/lists/220000000000",
"code" : "220000000005",
"display" : "Pharmaceutical dose form part"
}
]
}
}
],
"usage" : [
{
"country" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"jurisdiction" : {
"coding" : [
{
"system" : "urn:iso:std:iso:3166",
"code" : "EU",
"display" : "EU"
}
]
},
"language" : {
"coding" : [
{
"system" : "urn:ietf:bcp:47",
"code" : "en",
"display" : "en"
}
]
}
}
]
}
]
}
}
]
}
IG © 2021+ Gravitate Health Project. Package hl7.eu.fhir.ghepi#0.1.0 based on FHIR 5.0.0. Generated 2024-10-14
Links: Table of Contents |
QA Report
The Gravitate Health project has received funding from the IMI 2 Joint Undertaking under grant agreement No 945334.
This joint undertaking receives support from the EU H2020 research and innovation programme and EFPIA.
